Protocol Ledger

NCT03345823 · Phase III · ACTIVE NOT RECRUITING

A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433

Interventional Phase III clinical trial protocol NCT03345823 sponsored by AbbVie in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-03-21 Enrollment: 747 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT03345823
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)747 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03345823
Protocol FieldVerified Registry Value
NCT IdentifierNCT03345823
Consolidated Lead SponsorAbbVie
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment747 participants (ESTIMATED)
Registered Start Date2018-03-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for AbbVie across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI